SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society. Cancer Facts & Figures 2010. 2010. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf Accessed June 19, 2010.
  • 2
    Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program. 2004: 221-236.
  • 3
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with 3 intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 1002-1006.
  • 4
    McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976; 38: 1484-1493.
  • 5
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-242.
  • 6
    Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23: 4117-4126.
  • 7
    Pfreundschuh MG, Trumper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab — early stopping after the first interim analysis [abstract]. Proc Amer Soc Clin Oncol. 2004; 22. Abstract 6500.
  • 8
    Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 3121-3127.
  • 9
    Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. J Natl Compr Canc Netw. 2010;8:288-334. Available at: http://www.jnccn.org/content/8/3/288.short. Accessed September 28, 2010.
  • 10
    Ghafoor A, Jemal A, Cokkinides V, et al. Cancer Statistics for African Americans. CA Cancer J Clin. 2002; 52: 326-341.
  • 11
    Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer. 2008; 113: 3231-3241.
  • 12
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence. SEER 9. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Released April 2010, based on the November 2009 submission. Available at: www.seer.cancer.gov/publicdata. Accessed June 12, 2010.
  • 13
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence. SEER 13. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Released April 2010, based on the November 2009 submission. Available at: www.seer.cancer.gov/publicdata. Accessed June 12, 2010.
  • 14
    Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999; 8: 1117-1121.
  • 15
    Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000; 92: 1240-1251.
  • 16
    Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma. 2008; 49: 2099-2107.
  • 17
    Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  • 18
    Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007; 110: 695-708.
  • 19
    Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001. 2004. Available at: http://seer.cancer.gov/csr/1975_2001/ Accessed November 13, 2009.
  • 20
    Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985; 102: 596-602.
  • 21
    Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986; 104: 757-765.
  • 22
    Browne MJ, Hubbard SM, Longo DL, et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med. 1986; 104: 338-344.
  • 23
    Itoh K, Ohtsu T, Wakita H, et al. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Ann Oncol. 2000; 11: 1241-1247.
  • 24
    Linch DC, Smith P, Hancock BW, et al. A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol. 2000; 11( suppl 1): 87-90.
  • 25
    Lorusso V, Palmieri G, Bianco AR, et al. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: a randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol. 2000; 16: 149-154.
  • 26
    Department of Health and Human Services. Rituximab. Product approval information. Licensing Action. 1997. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1997/ritugen112697L.htm Accessed July 15, 2010.
  • 27
    Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001; 13: 325-334.
  • 28
    Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998; 92: 1927-1932.
  • 29
    Coiffier B, Lepage E, Herbrecht R, et al. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large-B-cell lymphoma (DLCL): interim results of a randomized GELA trial [abstract]. Blood. 2000;96:223A Abstract 950.
  • 30
    Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus 8 cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008; 9: 105-116.
  • 31
    Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-391.
  • 32
    Brown CC. The statistical comparison of relative survival rates. Biometrics. 1983; 39: 941-948.
  • 33
    Flowers CR, Glover R, Lonial S, Brawley OW. Racial differences in the incidence and outcomes for patients with hematological malignancies. Curr Probl Cancer. 2007; 31: 182-201.
  • 34
    The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987-994.
  • 35
    The A, Li Y, Reddy V, Davis R, Baird M, Foran J. A Comparative Study of Diffuse Large B-Cell Lymphoma (DLBCL) between African Americans and Caucasians: Single-Center Experience at the University of Alabama at Birmingham (UAB) [abstract]. Blood. 2007; 110: 4430.
  • 36
    Shenoy PJ, Bumpers K, King N, et al. Black/white differences in the treatment and outcomes of diffuse large B cell lymphoma: a matched cohort analysis [abstract]. Blood. 2009; 114: 1392.
  • 37
    Nabhan C, Morawa E, Bitran JD, et al. Patterns of care in follicular lymphoma (FL): are minorities being treated differently? Report from the National LymphoCare Study (NLCS) [abstract]. Blood. 2007; 110: 367.
  • 38
    Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109: 1857-1861.
  • 39
    The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997; 89: 3909-3918.
  • 40
    Percy C, Fritz A, Ries L. Conversion of neoplasms by topography and morphology from the International Classification of Diseases for Oncology, second edition to International Classification of Diseases for Oncology, third edition. 2001. Available at: http://seer.cancer.gov/tools/conversion/ICDO2-3manual.pdf Accessed March 19, 2009.
  • 41
    Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006; 15: 630-638.
  • 42
    Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006; 107: 265-276.
  • 43
    Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010 Oct 28. [Epub ahead of print].
  • 44
    Frankenfeld CL, Cerhan JR, Cozen W, et al. Dietary flavonoid intake and non-Hodgkin lymphoma risk. Am J Clin Nutr. 2008; 87: 1439-1445.
  • 45
    Willett EV, Morton LM, Hartge P, et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer. 2008; 122: 2062-2070.
  • 46
    De Roos AJ, Davis S, Colt JS, et al. Residential proximity to industrial facilities and risk of non-Hodgkin lymphoma. Environ Res. 2010; 110: 70-78.
  • 47
    Kricker A, Armstrong BK, Hughes AM, et al. Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer. 2008; 122: 144-154.
  • 48
    Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004; 23: 6524-6534.
  • 49
    Fisher SG, Fisher RI. The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications. Curr Opin Oncol. 2006; 18: 417-424.
  • 50
    Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995; 332: 1186-1191.
  • 51
    Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996; 88: 645-656.
  • 52
    Vilchez RA, Madden CR, Kozinetz CA, et al. Association between simian virus 40 and non-Hodgkin lymphoma. Lancet. 2002; 359: 817-823.
  • 53
    de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008; 6: 451-458.
  • 54
    Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009; 125: 398-405.
  • 55
    Ekstrom Smedby K, Vajdic CM, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008; 111: 4029-4038.
  • 56
    Huang T, Shenoy PJ, Sinha R, Graiser M, Bumpers KW, Flowers CR. Development of the Lymphoma Enterprise Architecture Database: a caBIG Silver level compliant system. Cancer Inform. 2009; 8: 45-64.
  • 57
    Morton LM, Purdue MP, Zheng T, et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1259-1270.
  • 58
    Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006; 7: 27-38.
  • 59
    Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 1937-1947.
  • 60
    Chen Y, Han T, Iqbal J, et al. Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. Am J Clin Pathol. 2010; 133: 305-313.
  • 61
    Chan WJ. Pathogenesis of diffuse large B cell lymphoma. Int J Hematol. 2010; 92: 219-230.
  • 62
    Powe NR, Cooper LA. Diversifying the racial and ethnic composition of the physician workforce. Ann Intern Med. 2004; 141: 223-224.
  • 63
    Lavizzo-Mourey R, Lumpkin JR. From unequal treatment to quality care. Ann Intern Med. 2004; 141: 221.
  • 64
    Groman R, Ginsburg J. Racial and ethnic disparities in health care: a position paper of the American College of Physicians. Ann Intern Med. 2004; 141: 226-232.
  • 65
    Kaplan SH, Greenfield S. The patient's role in reducing disparities. Ann Intern Med. 2004; 141: 222-223.
  • 66
    Hayes N, Rollins R, Weinberg A, et al. Cancer-related disparities: weathering the perfect storm through comprehensive cancer control approaches. Cancer Causes Control. 2005; 16( suppl 1): 41-50.
  • 67
    Reddy S, Shapiro M, Morton R Jr, Brawley OW. Prostate cancer in black and white Americans. Cancer Metastasis Rev. 2003; 22: 83-86.
  • 68
    Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002; 287: 2106-2113.
  • 69
    Brawley OW. Lung cancer and race: equal treatment yields equal outcome among equal patients, but there is no equal treatment. J Clin Oncol. 2006; 24: 332-333.
  • 70
    Cooper LA, Hill MN, Powe NR. Designing and evaluating interventions to eliminate racial and ethnic disparities in health care. J Gen Intern Med. 2002; 17: 477-486.
  • 71
    Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009; 15: 5494-5502.